Odyssey Health, Inc. Files 10-Q for Period Ending January 31, 2024

TL;DR

<b>Odyssey Health, Inc. has filed its quarterly report (10-Q) for the period ending January 31, 2024.</b>

AI Summary

Odyssey Health, Inc. (ODYY) filed a Quarterly Report (10-Q) with the SEC on March 22, 2024. Odyssey Health, Inc. filed a 10-Q report for the period ending January 31, 2024. The filing covers the fiscal second quarter of 2024. The company's fiscal year ends on July 31st. The filing was made on March 22, 2024. The company was formerly known as Odyssey Group International, Inc. until November 28, 2014.

Why It Matters

For investors and stakeholders tracking Odyssey Health, Inc., this filing contains several important signals. This 10-Q filing provides an update on Odyssey Health's financial performance and operational status for the second quarter of fiscal year 2024. Investors and stakeholders can use this report to assess the company's progress, identify potential risks, and make informed investment decisions.

Risk Assessment

Risk Level: low — Odyssey Health, Inc. shows low risk based on this filing. The filing is a standard 10-Q report, providing routine financial disclosures without immediate significant positive or negative indicators.

Analyst Insight

Monitor future filings for revenue growth, profitability trends, and any significant changes in the company's strategic direction or financial health.

Key Numbers

• 2024-01-31 — Period End Date (10-Q filing)
• 2024-03-22 — Filing Date (10-Q filing)
• 0731 — Fiscal Year End (Company fiscal calendar)

Key Players & Entities

• Odyssey Health, Inc. (company) — Filer name
• Odyssey Group International, Inc. (company) — Former company name
• NV (location) — State of incorporation
• 2024-01-31 (date) — Period of report
• 2024-03-22 (date) — Filed as of date
• 2014-11-28 (date) — Date of name change

FAQ

Industry Context

Odyssey Health, Inc. operates within the surgical and medical instruments & apparatus industry (SIC 3841).

Regulatory Implications

The company is subject to standard SEC reporting requirements for public companies, including the filing of quarterly reports (10-Q).

What Investors Should Do

1. Review the full 10-Q document for detailed financial statements and management discussion.
2. Analyze any disclosed revenue, expenses, and cash flow information.
3. Compare current period results with prior periods to identify trends.

Key Dates

• 2024-01-31: End of Reporting Period — The period covered by the 10-Q filing.
• 2024-03-22: Filing Date — Date the 10-Q was officially submitted to the SEC.

Year-Over-Year Comparison

This is a 10-Q filing, which is a quarterly update, and does not directly compare to a prior year's 10-Q in this header data.

Key Financial Figures

• $0.001 — nge on which registered Common Stock ($0.001 par value) ODYY OTC Indicate by che
• $1,000,000 — sets") to Oragenics in exchange for (i) $1,000,000 in cash; (ii) 8,000,000 shares of conve
• $325,672 — nd (iii) the assumption by Oragenics of $325,672 of our accounts payable. See Note 4. W
• $16,400,687 — tal value of consideration received was $16,400,687. The Assets include drug candidates f
• $1.63 — f Oragenics common stock were valued at $1.63 per share based a discount to the closi
• $2.30 — ice of Oragenics common stock which was $2.30 per share at January 31, 2024 as quoted
• $60,000 — ded to June 30, 2024. As consideration, $60,000 was added to the principal amount outst
• $0.20 — into 975,000 shares of common stock at $0.20

Filing Documents

• odyssey_i10q-013124.htm (10-Q) — 688KB
• odyssey_ex1003.htm (EX-10.3) — 9KB
• odyssey_ex1004.htm (EX-10.4) — 34KB
• odyssey_ex1005.htm (EX-10.5) — 77KB
• odyssey_ex3101.htm (EX-31.1) — 7KB
• odyssey_ex3102.htm (EX-31.2) — 8KB
• odyssey_ex3201.htm (EX-32.1) — 4KB
• odyssey_ex3202.htm (EX-32.2) — 4KB
• 0001683168-24-001645.txt (&nbsp;) — 4612KB
• odyy-20240131.xsd (EX-101.SCH) — 40KB
• odyy-20240131_cal.xml (EX-101.CAL) — 45KB
• odyy-20240131_def.xml (EX-101.DEF) — 171KB
• odyy-20240131_lab.xml (EX-101.LAB) — 324KB
• odyy-20240131_pre.xml (EX-101.PRE) — 291KB
• odyssey_i10q-013124_htm.xml (XML) — 530KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1

Financial Statements

Financial Statements 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Stockholders' Equity (Deficit) 5 Condensed Consolidated Statements of Cash Flows 6 Notes to the Condensed Consolidated

Financial Statements

Financial Statements 7 Item 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 24 Item 4

Controls and Procedures

Controls and Procedures 24

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1A

Risk Factors

Risk Factors 26 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 26 Item 5 Other Information 26 Item 6 Exhibits 27

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements Odyssey Health, Inc. Condensed Consolidated Balance Sheets (Unaudited) As of January 31, As of July 31, 2024 2023 Assets Current assets: Cash $ 166,140 $ 36,865 Research and development rebate due from the Australian government 22,625 276,566 Prepaid expenses and other current assets 70,715 92,457 Total current assets 259,480 405,888 Intangible assets, net of accumulated amortization of $ 0 and $ 5,376 – 49,905 Investment 13,790,403 – Total assets $ 14,049,883 $ 455,793 Liabilities and Stockholders' Deficit Current liabilities: Accounts payable $ 1,265,579 $ 1,797,656 Accrued wages 1,352,478 1,402,348 Accrued interest 151,250 142,032 Asset purchase liability 1,125,026 1,125,026 Notes payable, officers and directors 100,000 125,000 Notes payable, net of unamortized beneficial conversion feature, debt discount and closing costs of $ 149,529 and $ 280,340 1,385,138 2,019,660 Total current liabilities 5,379,471 6,611,722 Commitments and contingencies (Note 12) – – Stockholders' deficit: Preferred stock, $ 0.001 par value, 100,000,000 shares authorized, no shares issued or outstanding – – Common stock, $ 0.001 par value, 500,000,000 shares authorized, 94,433,050 and 79,067,879 shares issued and outstanding 94,434 79,068 Additional paid-in-capital 55,997,277 53,862,378 Accumulated deficit ( 47,421,299 ) ( 60,097,375 ) Total stockholders' equity (deficit) 8,670,412 ( 6,155,929 ) Total liabilities and stockholders' equity deficit $ 14,049,883 $ 455,793 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Odyssey Health, Inc. Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended January 31, Six Months Ended January 31, 2024 2023 2024 2023 In-process research and development expense $ – $ 170,000 $ – $ 170,000 Research and development expense 42,765 3,8

View Full Filing

View this 10-Q filing on SEC EDGAR